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Abstract The aim of this naturalistic observational study
was to investigate EEG alterations in patients under olan-
zapine treatment with a special regard to olanzapine dose
and plasma concentration. Twenty-two in-patients of a
psychiatric university ward with the monodiagnosis of
paranoid schizophrenia (ICD-10: F20.0), who received a
monotherapy of olanzapine were included in this study. All
patients had a normal alpha-EEG before drug therapy, and
did not suffer from brain-organic dysfunctions, as veriﬁed
by clinical examination and cMRI scans. EEG and olan-
zapine plasma levels were determined under steady-state
conditions (between 18 and 22 days after begin of treat-
ment). In 9 patients (40.9%), pathological EEG changes
(one with spike-waves) consecutive to olanzapine treat-
ment were observed. The dose of olanzapine was signiﬁ-
cantly higher in patients with changes of the EEG than in
patients without changes (24.4 mg/day (SD: 8.1) vs.
12.7 mg/day (SD: 4.8); T =- 4.3, df = 21, P\0.001). In
patients with EEG changes, the blood plasma concentration
of olanzapine (45.6 lg/l (SD: 30.9) vs. 26.3 lg/l (SD: 21.6)
tended to be also higher. The sensitivity of olanzapine
dosage to predict EEG changes was 66.7%, the speciﬁcity
100% (Youden-index: 0.67). EEG abnormalities during
olanzapine treatment are common. These are signiﬁcantly
dose dependent. Thus, EEG control recordings should be
mandatory during olanzapine treatment with special
emphasis on dosages exceeding 20 mg per day, although
keeping in mind that EEGs have only a limited predictive
power regarding future epileptic seizures.
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Introduction
Second-generation antipsychotics (SGA) were introduced
due to a smaller amount of adverse drug reactions (ADR),
particularly with regard to extrapyramidal syndromes
(EPS). However, the generally believed superiority of
SGAs in terms of efﬁcacy and safety has been challenged
in the last decade [1–3]. Most recently, in a Cochrane
review [4], the authors concluded that despite a slightly
better efﬁcacy of olanzapine when compared with other
SGAs, this has to be weighed against a larger weight gain
and its associated metabolic problems.
No signiﬁcant differences were reported for the risk to
develop epileptic seizures when olanzapine was compared
with newer atypical antipsychotic drugs such as amisulpi-
ride, quetiapine and risperidone, but seizure risk was lower
than under clozapine (RR = 0.15; CI: 0.04–0.58), based on
four randomized controlled trials [4]. However, epileptic
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Accordingly, epileptiform EEG abnormalities during
treatment with typical and atypical antipsychotics were
reported in psychiatric patients with a high variability
among SGAs, which was particularly high in patients under
clozapine [5] or olanzapine medication [6]. The authors
concluded that EEG abnormality risk may vary widely
among speciﬁc antipsychotics. It was assessed that this risk
was particularly high with clozapine and olanzapine,
moderate with risperidone and typical antipsychotics, and
low with quetiapine. In contrast to this ﬁnding, patients
treated with quetiapine had signiﬁcantly more EEG
abnormalities, although still rarely observed [7] when
compared with patients treated with haloperidol or
olanzapine.
For patients under clozapine treatment, therapeutic EEG
monitoring was suggested due to frequent EEG abnor-
malities, [8–11]. However, it may be debatable if a strict
EEG monitoring regime is necessary for patients treated
with olanzapine, given the rare incidence of seizures for
these patients [12].
In addition, it should be taken into account that ‘‘EEG
changes also vary with serum levels and are as necessary as
adequate serum levels for clinical efﬁcacy’’ [5, 13].
Moreover, co-medication such as benzodiazepine deri-
vates, which are frequently administered in psychotic
patients, could have limited the amount of olanzapine
treatment-related EEG alterations in prior studies.
Therefore, it was decided to conduct an observational
study with a clearly deﬁned patient population (mono-
therapy and monodiagnoses) to overcome possible biases
in other studies (such as inclusion of patients with a ben-
zodiazepine co-medication [6].
Method
Sample
Thirty in-patients of a psychiatric university ward treated
with olanzapine were included in the study. Of them, 14
patients (46.7%) were women, and 16 were men (53.3%).
The mean age was 44.6 years (range: 18–75 years; SD:
17.0).
All patients with an additional diagnosis other than
paranoid schizophrenia (ICD-10: F20.0) or with any addi-
tive medication (benzodiazepines, other antipsychotic, or
antidepressant medication) were excluded from the analy-
sis. All patients had at least two EEGs readings. For all
patients included in the further analysis, the ﬁrst exami-
nation was classiﬁed as normal-alpha-EEG. No patient had
a history of epilepsy, seizures or seizure-like episodes. An
absence of any other neurological disorder was also
necessary for inclusion in this study. In addition, patients
received a cMRI. Any signiﬁcant pathologic ﬁndings in the
cMRI served as exclusion criteria.
Eight screened patients had to be excluded from the
analysis because of meeting one or more of the exclusion
criteria. Therefore, 22 patients (7 women: 31.8%, 15 men:
68.2%; mean age: 44.8 years, range: 18–69 years, SD:
15.2) remained for the ﬁnal analysis.
Technical methods
EEGrecordingsfrom30psychiatricpatients(Departmentof
Psychiatry and Psychotherapy, University of Go ¨ttingen,
Germany) treated with olanzapine were graded to age, gen-
der, diagnoses, and treatment for type and severity of EEG
abnormalities. Dose and clinical factors were evaluated for
association with EEG abnormalities. EEG recordings were
performed according to the international 10/20 system [14]
with 21 electrodes. Plasma olanzapine levels were assessed
by high-performance liquid chromatography (HPLC) with
low-wavelength ultraviolet absorption detection (253 nm).
EEG and plasma levels were determined under steady-state
drug conditions (*18–22 days after starting). All EEGs
were evaluated by two independent investigators from the
Department of Clinical Neurophysiology of the University
of Go ¨ttingen, who were not involved in the study design,
analyses ortreatmentofthepatients.Theywere alsoblinded
to medication state.
EEG and cMRT were performed according to the stan-
dard procedures of the psychiatric university ward in all
in-patients. Only the ﬁrst EEG under olanzapine treatment
was considered for analyses. EEGs were classiﬁed as
normal (alpha-rhythm or variant without pathological
alterations), or displaying mild (regional theta activity,
pharmacogenic beta-activity), medium (regional theta-delta
activity), or severe abnormalities (sharp waves or spikes,
periodic patterns, suppression of EEG activity and gener-
alised slowing).
Statistical methods
Normal distribution of age of the patients, dose and
blood plasma level of olanzapine was assessed by the
Kolmogorov–Smirnov method. Student’s t-test and Pear-
son correlations were computed to test for statistical
associations. Sensitivity and speciﬁcity of olanzapine dose
and blood plasma level to predict EEG abnormalities were
graphically plotted with receiver operating characteristic
(ROC) curves. The statistical analysis was performed by
calculation of the area under the ROC curve (AUC) with
corresponding 95% conﬁdence intervals. The signiﬁcance
level was set at a = 0.05. All statistical tests were two-
sided. For the data analyses, the statistical software
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USA) was used.
Results
The mean dose of olanzapine was 17.5 mg per day (SD
8.6; range: 5–35 mg). The mean olanzapine blood plasma
level was 34.2 lg/l (SD: 26.9; range: 5–111 lg/l). The
dose and the plasma level were signiﬁcantly correlated
(Pearson’s correlation coefﬁcient, r = 0.67, P = 0.001).
Per deﬁnition, the ﬁrst EEG was regular in all patients
included in the study. The second EEG performed under
stable olanzapine medication was unchanged in 13 patients
(59.1%, normal EEG with a-rhythm). In 9 patients
(40.9%), pathological alterations were observed. Here, in
two (9.1%) patients pharmacogenic beta (b) activity, in
three patients (13.6%) other mild pathological abnormali-
ties, in three (13.6%) medium severe pathologic abnor-
malities, and in one patient (4.5%) severe pathologic
abnormalities with spike-wave complexes were observed
(see Table 1 for a more detailed description of the EEG
patterns). No seizures occurred. Neither age (Mann–
Whitney-U, Z =- 1.2, P = 0.24) nor gender (v
2 = 3.0,
df = 1, P = 0.08) were signiﬁcantly associated with
pathological EEG patterns.
The dose of olanzapine was signiﬁcantly higher in
patients with pathological EEG changes than in patients
without changes (24.4 mg/day (SD: 8.1) vs. 12.7 mg/day
(SD: 4.8); t =- 4.3, df = 21, P\0.001) (Fig. 1). A
respective trend was present for the blood concentration of
olanzapine (45.6 lg/l (SD: 30.9) vs. 26.3 lg/l (SD: 21.6)),
too (Fig. 2). Table 1 displays the demographic parameters
(age and sex), blood plasma levels of olanzapine and EEG
alterations for each dose of olanzapine.
The ROC curve with EEG alteration as dependent factor
and dose as predictor showed an AUC (area under the
curve) of 0.88 (95% CI: 0.71–1.00; P = 0.003). The best
cut-off value with respect to the best Youden—index was a
dose of olanzapine higher than 20 mg/day. The sensitivity
was 66.7%, the speciﬁcity 100% (Youden-index: 0.67), the
positive predictive value 100% and the negative predictive
value 81.3% (see Fig. 3).
Regarding the blood plasma level of olanzapine, no
predictor with a signiﬁcant AUC in the ROC curve was
identiﬁed. The best Youden—index would be a cut-off
value of above 25 lg/l with a good sensitivity of 88.9%,
but poor speciﬁcity of 38.5%.
The Pearson’s correlation between blood plasma level
and dosage was r = 0.57 (not signiﬁcant) in patients with a
pathologically altered EEG, whereas the correlation coef-
ﬁcient in patients with normal EEG was 0.729 (r = 0.729;
P = 0.005).
Discussion
The present study explored the association between olan-
zapine mediation and pathological alterations of the EEG
in a naturalistic patient sample. The results of the present
study show that olanzapine causes EEG alterations, and
that these alterations are predominantly dose dependent. A
suitable cut-off point for the prediction of EEG abnor-
malities was a daily dose of olanzapine higher than 20 mg,
which is in line with the dosage recommended by the
manufacturer. Age, sex and blood plasma levels were not
signiﬁcantly associated with EEG alterations. However, for
blood plasma level, a respective trend was identiﬁed, and
lack of signiﬁcance could be due to the limited statistical
power of the study.
Table 1 Olanzapine plasma level and EEG ﬁndings in patients with different olanzapine dose
Olanzapine
dose (mg)
N patients
(N male)
Mean age
(years)
Mean olanzapine
plasma level (lg/l)
EEG
abnormal. (%)
EEG
5 2 (1) 62.5 5.8 0 Normal a
10 5 (3) 51.0 12.9 20 Four with normal a, one with mild abnormalities
15 6 (4) 41.2 34.9 16.7 Five with normal a, one with mild abnormalities
20 3 (2) 36.0 48.2 33.3 Two with normal a, one with medium
abnormalities (theta-delta focus left temporal)
25 2 (2) 43.0 36.3 100 Two with medium abnormalities (2 with theta-
delta focus left fronto-temporal)
30 3 (2) 38.7 57.7 100 Three with mild abnormalities (two with
increased b-activity one with generalised
slowing of activity)
35 1 (1) 48.0 75.9 100 One severe abnormality with spike-wave
complexes
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in line with other ﬁndings in studies investigating the
effects of olanzapine on EEG (proportion of 35% in [7]). It
was also observed that EEG abnormalities were statisti-
cally signiﬁcantly increased with dose in the olanzapine
group [7]. In another study, a proportion of 44% of patients
with EEG abnormalities under olanzapine treatment was
described; however, this was based on a small sample size
(n = 9i n[ 15]). The proportion of EEG abnormalities in a
study by Centorrino et al. [6] was also comparable (38.5%).
The present study could not conﬁrm a statistical associ-
ation with the age of the patients, but identiﬁed a dose
dependencyoftheeffects,whichdidnotoccurinthestudyby
Centorinno and co-workers. However, patients in that study
were not treated under monotherapy conditions, which may
bias the comparability. Haring et al. [5] described an asso-
ciation between EEG abnormalities and blood plasma con-
centrations of olanzapine. This was not conﬁrmed in the
present study, which may be explained by the limited sta-
tistical power due to a small sample size. However, a
respective trend was observed also in the present study.
Olanzapine is antagonistic (among others) on the
dopaminergic receptors D1, D2 and D4 [19] which may
impact on the cortico-spinal excitability [19] and may be
partly expressed in EEG alterations. The EEG changes seen
in the present study are in accordance with a previous
report, in which an increase of theta activity by olanzapine
in healthy subjects (experimental data including P300) was
described [16]. Moreover, it was reported that olanzapine
may increase the delta activity in the posterior region [17].
The present results contrast ﬁndings by Pillmann et al. [18]
that epileptiform activity was not increased under olanza-
pine treatment.
Wichniak et al. [20] reported that the risk of epileptic
seizures under olanzapine treatment can be regarded as low
as long as olanzapine is administered as a monotherapy. In
addition to this, an excess increase in the dosage of olan-
zapine should be regarded with caution. Seizures due to
olanzapine treatment may be rare, nevertheless a fatal
status epilepticus has been described [21].
Strengths of the presented design include the focus on a
homogenous patient cohort (only schizophrenia as a mon-
odiagnosis according to ICD-10 F20.0, no relevant pre-
existing conditions, no seizure history, regular cMRT
without pathological ﬁnding in all participants) which has
been treated with a monotherapy. In addition, blood plasma
levels were recorded and all patients had a regular EEG
before treatment. Moreover, all EEGs were rated by two
certiﬁed investigators, who were not involved in the
treatment of the study patients. Furthermore, the raters
were blinded regarding the administered olanzapine dose.
The relatively small sample size of this study may be
regarded as a limitation. Therefore, other factors which
Fig. 1 Association between olanzapine dosage in mg and EEG
abnormalities (categorised into three groups). The box length is the
interquartile range
Fig. 2 Association between blood plasma concentration of olanza-
pine in lg/l and EEG abnormalities (categorised into three groups).
Circle shows a case with more than 1.5 box lengths from the upper or
lower edge of the box. The box length is the interquartile range
Fig. 3 Receiver operating characteristic (ROC) curve for the detec-
tion of EEG abnormalities using the olanzapine dosage
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ties in this patient group may have remained undetected
due to the limited statistical power. Another relevant lim-
itation is the observational design during a short period of
time. No weight-adjusted correlation between blood
plasma level and dosage was performed due to missing or
unreliable self-reported weight information. It would be
interesting to follow up all patients over a period of several
years to gain more insight into the relevance of the
observed EEG alterations for the manifestation of clinical
epileptic seizures. Thus, the current conclusions refer more
to EEG abnormalities than to clinical symptoms. In addi-
tion, it should be kept in mind that EEG abnormalities may
be limited in their power to predict future seizures, at least
in certain subpopulations of patients [22, 23]. However,
since epileptic seizures are relevant ADRs of antipsychotic
drugs, the EEG may help to identify patients at risk. Fur-
thermore, EEG measurements are reported to add infor-
mation for patients at risk for psychosis [24].
As mentioned above, it would be relevant to estimate the
risk of seizures under high-dose olanzapine treatment, and
the predictive value of EEG alterations. In order to achieve
this goal, a greater sample size, EEG-monitored follow-up
studies and observation of cohorts (including different
diagnoses and subgroups) may be useful. In addition,
implementing an integrated care network in the psychiatric
sector [25] for patients under olanzapine treatment may be
beneﬁcial. However, a challenge for this will be the treat-
ment practice with benzodiazepine derivates, which on the
one hand are administered for seizure prevention and
therapy, and on the other hand alter EEG abnormalities.
However, given the results of this and other studies, we
conclude that EEG control measurements should be man-
datory during olanzapine treatment with special caution if
dose levels exceed 20 mg per day, if the patient is treated
with concomitant medications, and if there is a history of
seizures in the past. However, it should be kept in mind that
EEGs have only a limited predictive power regarding the
occurrence of epileptic seizures in future. The use of
anticonvulsive medication should not be based on the
existence of EEG alterations. In addition, a switch to
another antipsychotic drug or change of its dosage may be
sometimes required.
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